Matsuda M, Catena T G, Vander Heide R S, Jennings R B, Reimer K A
Department of Pathology, Duke University Medical Center, Durham, NC 27710.
Cardiovasc Res. 1993 Apr;27(4):585-92. doi: 10.1093/cvr/27.4.585.
Previous studies have shown that cardiac protection by ischaemic preconditioning wanes before contractile function recovers; thus stunning is insufficient to cause preconditioning. To test whether reduced contractile effort is necessary for preconditioning induced protection, the effect on myocardial infarct size of restoring contractile function with dobutamine was examined in preconditioned and control dogs.
In two experimental groups (groups P and P+D), preconditioning was produced by four 5 min occlusions of the left anterior descending coronary artery, each separated by 5 min of reperfusion. Contractile function was assessed by sonomicrometry 5 min after completion of the preconditioning protocol. In group P+D, dobutamine (average dose = 5 micrograms.kg-1.min-1) was then infused intravenously to restore systolic shortening to baseline. The artery then was reoccluded for 40 min of sustained ischaemia followed by 4 d of reperfusion. Two additional groups of non-preconditioned control dogs (groups C and C+D) also underwent 40 min of coronary occlusion and 4 d of reperfusion. Group C+D received a dobutamine infusion beginning 15 min before and during the 40 min occlusion to match the dobutamine received in group P+D, whereas group C received normal saline.
Preconditioning caused mild postischaemic contractile dysfunction (50% decrease in systolic shortening) which was easily reversed by dobutamine treatment. Dobutamine also increased both the rate-pressure product and the left ventricular dP/dt in both treated groups (C+D and P+D). Histological infarct size was 12.3(SEM 2.0)% of the area at risk in the untreated control group (n = 11), and was reduced to 4.4(1.7)% in the untreated preconditioning group (n = 8; p < 0.05). Dobutamine increased non-preconditioned infarct size (group C+D) to 22.1(3.4)% (n = 7; p < 0.05). Infarct size in the dobutamine treated preconditioning group (P+D) was not significantly different from infarct size in group P (n = 8), at 6.1(2.5%).
In preconditioned hearts, dobutamine restored postischaemic contractile function but did not increase infarct size significantly. Thus reduced contractile effort is not required for the cardioprotective effect on ischaemic preconditioning.
以往研究表明,缺血预处理的心脏保护作用在收缩功能恢复之前就已减弱;因此,心肌顿抑不足以引发预处理。为了测试降低收缩力对于预处理诱导的保护作用是否必要,我们在预处理和对照犬中研究了用多巴酚丁胺恢复收缩功能对心肌梗死面积的影响。
在两个实验组(P组和P + D组)中,通过对左前降支冠状动脉进行4次5分钟的闭塞来产生预处理,每次闭塞间隔5分钟的再灌注。在预处理方案完成后5分钟,通过超声心动图测量评估收缩功能。在P + D组中,随后静脉输注多巴酚丁胺(平均剂量 = 5微克·千克⁻¹·分钟⁻¹)以将收缩期缩短恢复至基线水平。然后再次闭塞动脉40分钟持续缺血,随后再灌注4天。另外两组未预处理的对照犬(C组和C + D组)也经历了40分钟的冠状动脉闭塞和4天的再灌注。C + D组在40分钟闭塞前15分钟开始并在闭塞期间接受多巴酚丁胺输注,以匹配P + D组接受的多巴酚丁胺剂量,而C组接受生理盐水。
预处理导致缺血后轻度收缩功能障碍(收缩期缩短减少50%),多巴酚丁胺治疗可轻松逆转。多巴酚丁胺还增加了两个治疗组(C + D组和P + D组)的心率 - 血压乘积和左心室dP/dt。在未治疗的对照组(n = 11)中,组织学梗死面积为危险区域的12.3(标准误2.0)%,在未治疗的预处理组(n = 8;P < 0.05)中降至4.4(1.7)%。多巴酚丁胺使未预处理的梗死面积(C + D组)增加至22.1(3.4)%(n = 7;P < 0.05)。多巴酚丁胺治疗的预处理组(P + D组)的梗死面积为6.1(2.5)%,与P组(n = 8)的梗死面积无显著差异。
在预处理的心脏中,多巴酚丁胺恢复了缺血后的收缩功能,但未显著增加梗死面积。因此,对于缺血预处理的心脏保护作用,不需要降低收缩力。